Mendelian randomization analysis reveals a causal effect of urinary sodium/creatinine ratio on kidney function in Europeans by Zhang, Yuemiao et al.
                          Zhang, Y., Zheng, J., Gaunt, T. R., & Zhang, H. (2020). Mendelian
randomization analysis reveals a causal effect of urinary
sodium/creatinine ratio on kidney function in Europeans. Frontiers in
Bioengineering and Biotechnology, [662].
https://doi.org/10.3389/fbioe.2020.00662
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.3389/fbioe.2020.00662
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Frontier Media at
https://www.frontiersin.org/articles/10.3389/fbioe.2020.00662/full. Please refer to any applicable terms of use of
the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
fbioe-08-00662 July 3, 2020 Time: 20:0 # 1
PERSPECTIVE

















†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Computational Genomics,
a section of the journal
Frontiers in Bioengineering and
Biotechnology
Received: 31 December 2019
Accepted: 28 May 2020
Published: 07 July 2020
Citation:
Zhang Y, Zheng J, Gaunt TR and
Zhang H (2020) Mendelian
Randomization Analysis Reveals
a Causal Effect of Urinary
Sodium/Urinary Creatinine Ratio on
Kidney Function in Europeans.
Front. Bioeng. Biotechnol. 8:662.
doi: 10.3389/fbioe.2020.00662
Mendelian Randomization Analysis
Reveals a Causal Effect of Urinary
Sodium/Urinary Creatinine Ratio on
Kidney Function in Europeans
Yue-miao Zhang1†, Jie Zheng2*†, Tom R. Gaunt2,3 and Hong Zhang1*
1 Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease,
Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry
of Education, Beijing, China, 2 MRC Integrative Epidemiology Unit (IEU), Bristol Medical School, University of Bristol, Oakfield
House, Bristol, United Kingdom, 3 National Institute for Health Research (NIHR), Bristol Biomedical Research Centre, Bristol,
United Kingdom
Salt restriction was recommended in clinical practice guideline for chronic kidney
disease (CKD) treatment, but its effect on kidney outcomes remains conflicting. We
aimed to test the causal effect of salt intake, using estimated 24-h sodium excretion
from spot urinary sodium/urinary creatinine (UNa/UCr) ratio as a surrogate, on renal
function using two-sample Mendelian randomization (MR). Genetic instruments for
UNa/UCr were derived from a recent genome-wide association study of 218,450
European-descent individuals in the UK Biobank. Kidney outcomes were creatinine-
based estimated glomerular filtration rate (eGFRcrea) (N = 567,460) and CKD
(eGFRcrea < 60 ml/min/1.73 m2, N cases = 41,395, N controls = 439,303) from
the CKDGen consortium. Cystatin C-based eGFR (eGFRcys) and eGFRcrea single-
nucleotide polymorphisms associated with blood urea nitrogen (BUN) were used for
sensitivity analyses. MR revealed a causal effect of UNa/UCr on higher eGFRcrea
[β = 0.14, unit change in log ml/min/1.73 m2 per UNa/UCr ratio; 95% confidence
interval (CI) = 0.07 – 0.20, P = 2.15 × 10−5] and a protective effect against CKD
risk (odds ratio = 0.24, 95% CI = 0.14 to 0.41, P = 1.20 × 10−7). The MR findings
were confirmed by MR-Egger regression, weighted median MR, and mode estimate
MR, with less evidence of existence of horizontal pleiotropy. Consistent positive causal
effect of UNa/UCr on eGFRcys was also detected. On the other hand, bidirectional
MR suggested inconclusive results of CKD, eGFRcrea, eGFRcrea (BUN associated),
and eGFRcys on UNa/UCr. The average 24-h sodium excretion was estimated to be
approximately 2.6 g per day for women and 3.7 g per day for men. This study provides
evidence that sodium excretion, well above the recommendation of <2 g per day of
sodium intake, might not have a harmful effect on kidney function. Clinical trials are
warranted to evaluate the sodium restriction target on kidney function.
Keywords: salt restriction, urinary sodium/urinary creatinine ratio, kidney function, Mendelian randomization,
causal effect
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INTRODUCTION
Chronic kidney disease (CKD) accounts for 10% to 15%
population worldwide, which is associated with high annual
rates of mortality and cardiovascular complications (Xie
et al., 2018). Identifying potentially modifiable risk factors for
CKD is critical in order to devise effective, population-based
preventive strategies.
A salt restriction <90 mmol per day (equivalent to 5 g per day
of salt or 2 g per day of sodium) is recommended in the 2012
Kidney Disease: Improving Global Outcomes (KDIGO) clinical
practice guideline (Kidney Disease: Improving Global Outcomes
[KDIGO] and CKD Work Group, 2012). The Working Group
graded this recommendation as “1C,” indicating that controlling
salt intake can be evaluated as a candidate for developing a
policy or a performance measure (Grade level 1), but from
low quality of evidence (Grade C). This recommendation was
mainly based on expert opinion and extrapolation from previous
studies between sodium intake and blood pressure. Observational
epidemiology studies have indicated that sodium intake was
positively associated with blood pressure and proteinuria, which
are strong predictors of CKD progression and cardiovascular
diseases (CVDs) (He et al., 2013). In addition, existing clinical
trials in sodium restriction showed significant reductions in
blood pressures and proteinuria (Vogt et al., 2008; Suckling
et al., 2010; Slagman et al., 2011; Graudal et al., 2012; de
Brito-Ashurst et al., 2013). However, prospective cohort studies
have reported conflicting findings on the association between
dietary sodium intake and CVD (Cook et al., 2007; O’Donnell
et al., 2011, 2014). Moreover, emerging studies suggested that
extreme strict sodium control may be harmful rather than
beneficial as previously recommended in CKD patients (Fan
et al., 2014). Debates about optimal sodium intake in the general
population are still ongoing (Mente et al., 2016, 2018). During the
2017 KDIGO controversies conference, stakeholders questioned
whether a level 1C recommendation of sodium restriction (<2 g
of sodium per day) was too strong based on the current evidence
(Cheung et al., 2019).
Given that few randomized controlled trials have been
conducted to infer causality between salt intake and kidney
outcomes, the genetic variants associated with potential risk
factors offer the opportunity to test the causal effect of salt intake
on CKD through Mendelian randomization (MR) (Smith and
Ebrahim, 2003; Zheng et al., 2017). In essence, MR exploits the
random allocation of genetic variants at conception and therefore
is less susceptible to confounding compared to traditional
observational studies. Furthermore, MR studies give the effects
of lifetime exposures and so could evaluate the long-term effect.
Recently, Zanetti et al. performed genome-wide association
studies (GWASs) of urinary electrolyte excretion, including the
urinary sodium/urinary creatinine (UNa/UCr) ratio, in up to
327,616 unrelated individuals of European ancestry from the UK
Biobank (Zanetti et al., 2019). Since spot urine samples were
commonly used to estimate 24-h sodium excretion as a surrogate
for salt intake (Lee et al., 2013; Mente et al., 2016, 2018), we aimed
to assess the causal effect of salt intake, using UNa/UCr as proxy,
on kidney function in Europeans using MR (Hemani et al., 2018).
MATERIALS AND METHODS
Genetic Predictors of Urinary Sodium
Excretion
In a recent genetic study of urinary sodium excretion
normalized for creatinine (calculated as UNa/UCr), 327,616
eligible individuals from the UK Biobank were included and two-
thirds of the sample (n = 218,450) were randomly selected for
discovery GWAS (Zanetti et al., 2019). Association analysis was
conducted using linear regression of UNa/UCr levels on imputed
genotypes, assuming an additive model between phenotype
and genotype dosages. The model was adjusted for age, sex,
batch, and the first 10 genotype principal components. Six
conditional distinguished genetic variants strongly associated
with UNa/UCr (P < 5 × 10−8) were selected as candidate
instruments (Supplementary Table S1).
Genetic Associations of Kidney Function
Phenotypes
Creatinine-based estimated glomerular filtration rate (eGFRcrea)
and CKD (eGFRcrea < 60 ml/min/1.73 m2, binary phenotype)
were used as proxies for kidney function phenotypes. eGFRcrea
was estimated from serum creatinine using the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula (Levey
et al., 2009). It was estimated as 141 × min(Scr/κ, 1)α
× max(Scr/κ, 1)−1.209 × 0.993Age × 1.018 (if female)_1.159 (if
black), where Scr is the serum creatinine, κ is 0.7 for females
and 0.9 for males, α is -0.329 for females and -0.411 for males,
min indicates the minimum of Scr/κ or 1, and max indicates the
maximum of Scr/κ or 1. GWAS summary statistics of eGFRcrea
(N = 567,460) and CKD (N cases = 41,395; N controls = 439,303;
N total = 480,698) from the CKDGen consortium were utilized
(Wuttke et al., 2019). The GWASs were imputed using the 1000
Genomes phase 1 v3 training set with 38 million variants. Genetic
associations were adjusted for study specific covariates such as age
and sex, and the first 10 principal components were also used as
covariates in the association model of the GWAS to control for
the population stratification.
Mendelian Randomization
MR is an instrumental variable method that uses genetic
variants as instruments to test the casual relationships
between an exposure (e.g., UNa/UCr) and an outcome
(e.g., eGFRcrea/CKD). The causal association between the
exposure and the outcome will be valid when the three core
MR assumptions were satisfied (Figure 1). In our initial MR
analysis, UNa/UCr was treated as exposure and eGFRcrea/CKD
as outcomes, using the UNa/UCr-associated single-nucleotide
polymorphisms (SNPs) as instrument variables. We used the
random-effect inverse variance weighted (IVW) method (Burgess
et al., 2013) to estimate the MR effect, which pools the individual
SNP Wald estimator (Lawlor et al., 2008) by meta-analysis. The
Cochrane’s Q and Rocker’s Q statistics were used to estimate
the level of heterogeneity of the IVW and MR-Egger regression
separately, in which the degree of freedom for Cochrane’s Q is
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FIGURE 1 | The diagram and three key assumptions of Mendelian randomization.
the number of SNPs minus one and that for Rocker’s Q is the
number of SNPs minus two.
We further tested the MR assumptions using the following
sensitivity analyses. MR-Egger regression (Bowden et al., 2015)
was used to test pleiotropic effects of the instruments on
outcomes, independent of exposures. The MR-Egger regression
intercept was recorded as an indicator of pleiotropy. We also
performed MR analyses using the weighted median MR approach
(Bowden et al., 2016) and the mode estimate MR approach
(Hartwig et al., 2017), which provides consistent causal estimates
of the exposure on the outcome even when up to 50% (or even
0%) of the information contributing to the analysis comes from
genetic variants that exhibit pleiotropy. If all approaches (i.e.,
IVW MR, MR-Egger regression, weighted median MR, and mode
estimate MR) provide consistent causal estimates of UNa/UCr on
eGFRcrea/CKD, the MR findings will be more robust. To exclude
the influence of pleiotropy instruments on the MR estimates,
we applied MR-PRESSO (Verbanck et al., 2018) as another
sensitivity analysis, which attempts to reduce heterogeneity in the
estimate of the causal effect by removing SNPs that contribute to
the heterogeneity disproportionately more than expected.
Directionality Analysis
Steiger Filtering
When applying MR, we assume that SNPs used as proxies
of UNa/UCr exert their primary association on UNa/UCr and
that any correlation with eGFRcrea or CKD is a consequence
of a causal effect of UNa/UCr on eGFRcrea or CKD. We
therefore performed Steiger filtering analyses (Hemani et al.,
2018), implemented in the TwoSampleMR R package, to test the
directionality of UNa/UCr instruments. The underline concept
of Steiger filtering is a simple inequality. Given that phenotype A







since cor(gi, B)2 = cor(A, B)2 ∗ cor(gi, A)2, where “cor” denotes
correlation, and the vector g contains a set of SNPs that influence
phenotype A. For any instrument that had a cor(gi, A)2 < cor(gi,
B)2, they showed evidence of primarily affecting eGFR rather
than UNa/UCr. We thus removed these UNa/UCr instruments
and performed the MR analyses using the remaining instruments.
Bidirectional MR
To investigate the potential reverse causality of eGFRcrea/CKD
on UNa/UCr, we conducted a bidirectional MR. We first
found 256 conditional independent variants associated
with eGFRcrea and 23 independent variants associated
with CKD (Supplementary Table S2) using the linkage
disequilibrium clumping (r2 < 0.001) function implemented
in the TwoSampleMR R package. We then used eGFRcrea
or CKD as exposures and UNa/UCr as the outcome for the
bidirectional MR. Considering that eGFRcrea has GFR and
marker determinants, we further performed sensitivity analyses
by using blood urea nitrogen (BUN) GWAS (Wuttke et al.,
2019) to prioritize eGFRcrea-associated SNPs as exposures. More
specifically, we required the eGFRcrea SNPs be associated with
BUN in the opposite direction (since higher GFR would lead to
lower BUN) and the eGFRcrea SNPs be associated with BUN
with a Bonferroni-corrected significance. In addition, cystatin C,
an alternative biomarker of kidney function, was measured in
a subset of European ancestry participants from the CKDGen
consortium (N = 32,861) (Li et al., 2017). Cystatin C-based
eGFR (eGFRcys) could be estimated as 76.7 × serum cystatin C
(Levey et al., 2011). To further exclude the possible bias caused
by creatinine, we extracted five SNPs that robustly associated
with eGFRcys (Li et al., 2017) and used them as instruments for a
sensitivity MR analysis against UNa/UCr.
MR and Visualization Software
The MR results were presented as scatter plots and forest
plots using a code derived from the ggplot2 package in R1.
All MR and sensitivity analyses were conducted using the
1https://cran.r-project.org/web/packages/ggplot2/index.html
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TwoSampleMR R package2 (Hemani et al., 2018). MR-PRESSO
test was conducted by using the MR-PRESSO R package3. The
number of distributions was set to 10,000, and the threshold
was set to 0.05.
24-h Urinary Sodium Estimation
The exact intake of sodium cannot be measured precisely but can
be estimated from 24-h sodium excretion (Kawano et al., 2007).
Thus, to estimate the sodium intake, we used the INTERSALT
(International Cooperative Study on Salt, Other Factors, and
Blood Pressure) equation (Brown et al., 2013), developed in a
sample of 3,093 European-descent individuals aged 20–59 years,
to estimate the 24-h urine sodium excretion based on the reported
spot urine measurements. The equation was described as follows.
For men:
24-h sodium excretion (mg) = 23 × {25.46 + [0.46 × spot
urine sodium (mmol/L)] − [2.75 × spot urine
creatinine (mmol/L)] − [0.13 × spot urine potassium
(mmol/L)] + [4.10 × body mass index (kg/m2)] + [0.26 × age
(years)]}.
For women:
24-h sodium excretion (mg) = 23 × {5.07 + [0.34 × spot
urine sodium (mmol/L)] − [2.16 × spot urine
creatinine (mmol/L)] − [0.09 × spot urine potassium
(mmol/L)] + [2.39 × body mass index (kg/m2)] + [2.35 × age
(years)]− [0.03× age2 (years)]}.
RESULTS
Effect of UNa/UCr on eGFRcrea and CKD
Figure 2 showed the MR results of UNa/UCr on eGFRcrea and
CKD. For eGFRcrea, the IVW MR suggested that UNa/UCr was
positively associated with eGFRcrea [β = 0.14, unit change in
log ml/min/1.73 m2 per UNa/UCr ratio; 95% confidence interval
(CI) = 0.07 – 0.20, P = 2.15 × 10−5, Figure 2A]. Similarly,
the IVW MR suggested that increased UNa/UCr was associated
with reduced CKD risk [odds ratio (OR) = 0.24, 95% CI = 0.14
to 0.41, P = 1.20 × 10−7, Figure 2B]. The SNP MR results
presented by the forest plots suggested that the causal effects of
UNa/UCr on eGFRcrea/CKD were similar across instruments,
and the observed MR findings were not massively influenced
by any single instrument (Figures 2A,B). Figures 2C,D showed
scatter plots of the SNP-outcome associations against the SNP-
UNa/UCr associations, allowing visualization of the causal effect
for individual SNP on eGFRcrea/CKD.
Cochrane’s Q test (P = 7.03 × 10−7 and 5.83 × 10−3 for
eGFRcrea and CKD as outcomes, respectively) and Rocker’s
Q-test (P = 6.72× 10−7 and 2.29× 10−3 for eGFRcrea and CKD
as outcomes, respectively) suggested the presence of considerable
heterogeneity in the analysis. However, the MR-Egger intercept
suggested little evidence of horizontal pleiotropy (P = 0.65





Table 1 showed the MR estimates of UNa/UCr on eGFRcrea and
CKD using other sensitivity MR approaches, which are more
robust to pleiotropy. For eGFRcrea, the IVW MR result was
consistent with the casual estimates using MR-Egger regression
(β = 0.32, 95% CI = 0.06 – 0.58, P = 1.66 × 10−2), weighted
median MR (β = 0.07, 95% CI = 0.04 – 0.11, P = 8.68× 10−6), and
mode-based estimate MR approaches (β = 0.05, 95% CI = 0.02 –
0.09, P = 1.82 × 10−2), which increased the robustness of the
MR results. For CKD, the IVW MR estimates were concordant
in direction with the MR estimates using MR-Egger (OR = 0.32,
95% CI = 0.02 – 4.97, P = 0.46), weighted median MR (OR = 0.23,
95% CI = 0.14 – 0.40, P = 1.40 × 10−7), and mode-based MR
approaches (OR = 0.20, 95% CI = 0.10 – 0.41, P = 7.55 × 10−3).
In consistent with these results, we also observed positive causal
effect of UNa/UCr on eGFRcys (Supplementary Table S4).
Given that some of the instruments might be influenced by
horizontal pleiotropy, we applied the MR-PRESSO outlier test
and identified three UNa/UCr instruments as potential outliers.
The MR estimate after removing the outliers identified by MR-
PRESSO suggested a consistent positive effect of UNa/UCr on
eGFRcrea (MR-PRESSO estimate: β = 0.129, 95% CI = 0.076 –
0.182, P = 4.14× 10−2; Supplementary Table S5).
Directionality Tests
The Steiger filtering results suggested that all instruments
were primarily influencing UNa/UCr than affecting eGFRcrea
as a consequence (Supplementary Table S6), which further
confirmed the robustness of the instruments. As shown in
Figure 3, bidirectional MR using CKD, eGFRcrea, eGFRcrea
(BUN associated), and eGFRcys as exposures and UNa/UCr as
an outcome suggested inconsistent evidence of causal effect of
kidney function on UNa/UCr (Supplementary Table S7).
Sodium Intake Estimation
The mean age, body mass index, UNa/UCr, and urinary
potassium/UCr were 56.88, 27.39, 10.60, and 8.48, respectively,
in the discovery population and were 56.87, 27.42, 10.62, and
8.44, respectively, in the replication population (Zanetti et al.,
2019). Using these baseline characteristics, the average 24-h
sodium excretion was estimated to be approximately 2.6 g per
day for women and 3.7 g per day for men, well above the
recommended restriction of <2 g per day of sodium intake
(Supplementary Table S8).
DISCUSSION
Sodium intake was reported to be one of the most important
modifiable risk factors influencing blood pressure and
proteinuria, yet its impact on renal outcomes is uncertain.
Using a two-sample MR approach, we tested the causal effect of
sodium intake, using estimated 24-h sodium excretion from a
spot UNa/UCr ratio as a surrogate, on kidney function. We found
that each unit increase in the UNa/UCr ratio was associated
with a 0.14 unit increase in log(eGFRcrea) and with reduced
CKD risk (OR = 0.24). These MR findings were confirmed by
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FIGURE 2 | Forest plot and scatter plot for causal effects of urinary sodium/creatinine ratio on eGFRcrea and CKD. The forest plot shows the Wald ratio estimate of
each UNa/UCr instrument on eGFRcrea (A) or CKD (B). The scatter plots display the causal estimates of UNa/UCr (x-axis) against eGFRcrea (C) or CKD (D). Each
point refers to one UNa/UCr instrument. The slopes of the lines represent the causal estimates of UNa/UCr on CKD or eGFRcrea using inverse variance weighted,
MR-Egger regression, weighted median, and mode estimate approaches. The y-intercept of the MR-Egger regression line is an estimate of the degree of horizontal
pleiotropy in the dataset. Notation: CKD, chronic kidney disease; eGFRcrea, creatinine-based estimated glomerular filtration rate; IVW, inverse variance weighted;
UNa/UCr, urinary sodium/urinary creatinine ratio.
MR-Egger regression, weighted median MR, and mode estimate
MR, which suggested less evidence of existence of horizontal
pleiotropy. Steiger filtering suggested less evidence of reverse
causality of CKD on UNa/UCr. Cochrane’s Q and Rocker’s Q
statistics suggested the presence of considerable heterogeneity in
the analysis. However, the MR-Egger intercept suggested little
evidence of horizontal pleiotropy. Consistent positive causal
effect of UNa/UCr on eGFRcys was also detected. Bidirectional
MR using CKD, eGFRcrea, eGFRcrea (BUN associated), and
eGFRcys as exposures showed weak evidence supporting a causal
relationship for kidney function on UNa/UCr. The average
24-h sodium excretion was estimated to be approximately
2.6 g per day for women and 3.7 g per day for men, well
above the recommendation of <2 g per day of sodium intake
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TABLE 1 | Mendelian randomization analyses of causal effects of urinary sodium/urinary creatinine ratio on eGFRcrea and CKD.
Trait Number of SNPs Methods Estimator (95% CI) P
eGFRcrea 6 MR IVW β = 0.14 (0.07 – 0.20) 2.15 × 10−5
6 MR-egger β = 0.32 (0.06 – 0.58) 1.66 × 10−2
6 MR-weighted median β = 0.07 (0.04 – 0.11) 8.68 × 10−6
6 MR-weighted mode β = 0.05 (0.02 – 0.09) 1.82 × 10−2
CKD 6 MR IVW OR = 0.24 (0.14 – 0.41) 1.20 × 10−7
6 MR-egger OR = 0.32 (0.02 – 4.97) 0.46
6 MR-weighted median OR = 0.23 (0.14 – 0.40) 1.40 × 10−7
6 MR-weighted mode OR = 0.20 (0.10 – 0.41) 7.55 × 10−3
The confidence interval of MR-Egger estimates was wider compared to that of other methods because the statistical power of the MR-Egger was, in general, lower than
that of MR IVW and weighted median. CKD, chronic kidney disease; eGFRcrea, creatinine-based estimated glomerular filtration rate; MR, Mendelian randomization; IVW,
inverse variance weighted, OR, odds ratio; SNP, single-nucleotide polymorphism.
FIGURE 3 | Mendelian randomization analyses of causal effects of eGFR/CKD on urinary sodium/creatinine ratio. BUN, blood urea nitrogen; eGFRcrea,
creatinine-based estimated glomerular filtration rate; eGFRcrea (BUN associated), the eGFRcrea-associated SNPs were required to be associated with BUN in
opposite direction (since higher GFR would lead to lower BUN) and to be associated with BUN with a Bonferroni-corrected significance; eGFRcys, cystatin C-based
estimated glomerular filtration rate.
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in the KDIGO guideline. Our results support that reducing
dietary sodium intake under 2 g per day in CKD might be
overcontrolled and may not have a beneficial effect on reducing
CKD risk as expected.
Sodium intake was regarded as one of the important
modifiable risk factors for CKD progression. The exact intake of
sodium cannot be measured precisely but can be estimated from
dietary questionnaires or 24-h sodium excretion (Kawano et al.,
2007). However, questionnaires are usually self-reported and
require calculations by a nutritionist and thus may be imperfect
measures of sodium intake (Leiba et al., 2005), while the 24-h
urine sample collection is limited to poor compliance and cost.
Thus, studies usually used spot urine samples to estimate 24-h
sodium excretion as a surrogate for sodium intake (Mente et al.,
2016, 2018). To compensate for variation in urine concentration,
urinary sodium corrected by urinary creatinine could be used
for assessing sodium excretion in urine over 24-h (Lee et al.,
2013). Using these methods, previous observational studies have
provided inconsistent results on the effects of dietary sodium
intake on the risk of CKD. Some studies suggested that urinary
sodium excretion was associated with increased risk of CKD
progression and incidence of end-stage renal disease (ESRD) (Mc
Causland et al., 2012; Vegter et al., 2012; Ohta et al., 2013; Mc
Quarrie et al., 2014), while others indicated that urinary sodium
excretion was not associated with the risk of CKD or renal failure
(Dunkler et al., 2013; Fan et al., 2014; Smyth et al., 2014), even
protected against cumulative incidence of ESRD (Ekinci et al.,
2011; Thomas et al., 2011). The inconsistent results may be due to
the fact that these studies were observational studies that cannot
make causal inference.
Until now, previous trials mainly focused on the blood
pressure lowering effect of sodium control, but there are limited
evidence detailing the effects of sodium restriction in CKD
patients. For example, the Holland Nephrology Study (HON-
EST) suggested that the addition of a low-sodium diet further
reduced 11 mmHg systolic blood pressure in patients with
treatment with an angiotensin converting enzyme inhibitor
(Slagman et al., 2011). Vogt found reductions of 6/3 mmHg
systolic blood pressure/diastolic blood pressure in proteinuric
patients without diabetes who received a low-sodium diet (Vogt
et al., 2008). Two more recent studies provided new clinical
trial data from randomized, double-blind, crossover trials in
patients with stages 3 and 4 CKD (McMahon et al., 2013;
Saran et al., 2017). They found that salt restriction resulted
in statistically significant reductions of blood pressure and
albuminuria. However, although salt intake has been extensively
suggested to be associated with blood pressure, high sodium
intake-related increase in blood pressure might not entirely
explain the elevated risk of CKD progression and renal failure
in patients with CKD. What’s more, it must be noted that
it is unable to compare the clinical outcomes among patients
with urinary sodium excretion <2 g per day recommended in
clinical practice guideline, which appears difficult to achieve.
Results from most trials showed that only high urinary sodium
excretion (approximately 150–200 mmol or 3.5–4.5 g sodium
per day), well above the recommended limit (2 g sodium per
day), was associated with increased risk of CKD progression
or all-cause mortality (Norris et al., 2006; Lambers et al.,
2012; McMahon et al., 2013; He et al., 2016). Thus, using
these data is hard to assess whether sodium restriction <2 g
per day is suggestively hazardous or intuitively advantageous
(Anderson and Ix, 2013).
In the current study, we used the two-sample MR approach
to test the causal effect of UNa/UCr on kidney outcomes. We
further estimated the 24-h urine sodium excretion to estimate
sodium intake using the previously published sodium excretion
estimating equation based on spot urine measurements, which
was developed and validated in European populations (Brown
et al., 2013). We found that UNa/UCr showed causal effect
on higher eGFRcrea and lower CKD risk, while weak evidence
of causal association between kidney function and UNa/UCr
was observed. Using baseline characteristics of the UK Biobank
participants, the average 24-h sodium excretion was estimated
to be approximately 2.6 g per day for women and 3.7 g per day
for men. Previous studies suggested that this estimation equation
might underestimate the urinary sodium excretion (Allen et al.,
2017). Although potential bias exists in estimating 24-h sodium
excretion using casual urinary test (Dougher et al., 2016), our
results support that reducing dietary sodium intake under 2 g
per day in CKD was too restrictive and might not be beneficial to
reduce the risk of CKD development or progression as expected.
Several limitations should be mentioned in this study. First,
24-h urine collection was estimated rather than performed in the
study population; target levels of UNa/UCr for protecting effects
were not evaluated. In the future, additional large randomized
controlled trials are required to determine the optimal target
sodium intake. Second, we currently have limited access to
the individual level genotype and phenotype data to perform
further stratification of groups by instruments or outcomes and
distributions. This type of analysis is needed to determine the
optimal target of sodium intake in CKD in the future. Third,
this study is limited to the only six instruments of UNa/UCr,
even though they were derived from the well-powered and most
recent UNa/UCr GWAS. Most of the current MR sensitivity
analysis methods such as MR-Egger regression and weighted
median need a large number of independent instrumental
SNPs in order to test for pleiotropy. Thus, the MR results
presented in this paper should be taken with caution. Fourth,
the MR Steiger filtering approach has limitations, i.e., some
levels of horizontal pleiotropy, where the SNP influences the
outcome through some pathways other than the exposure,
could induce problems because this is a means by which
the instrument is invalid. Besides, some levels of unmeasured
confounding between the exposure and the outcome could
lead to inference of the wrong causal direction. We therefore
applied a well-validated method MR-PRESSO. After controlling
for pleiotropy instruments, our finding was still consistent.
Finally, as in most epidemiological studies, MR assumes a linear
relation between UNa/UCr and eGFR/CKD, which might not
invariably be the case.
In conclusion, we found that a higher UNa/UCr ratio, which
reflects proportionally higher salt intake, showed causal effects on
higher eGFR and lower CKD risk. Further long-term studies to
determine optimal target of sodium intake in CKD are required.
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